1
|
Ontsira Ngoyi EN, Atipo Ibara BI, Moyen R, Ahoui Apendi PC, Ibara JR, Obengui O, Ossibi Ibara RB, Nguimbi E, Niama RF, Ouamba JM, Yala F, Abena AA, Vadivelu J, Goh KL, Menard A, Benejat L, Sifre E, Lehours P, Megraud F. Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo. Helicobacter 2015; 20:316-20. [PMID: 25585658 DOI: 10.1111/hel.12204] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACK GROUND Helicobacter pylori infection is involved in several gastroduodenal diseases which can be cured by antimicrobial treatment. The aim of this study was to determine the prevalence of H. pylori infection and its bacterial resistance to clarithromycin, fluoroquinolones, and tetracycline in Brazzaville, Congo, by using molecular methods. MATERIAL AND METHODS A cross- sectional study was carried out between September 2013 and April 2014. Biopsy specimens were obtained from patients scheduled for an upper gastrointestinal endoscopy and were sent to the French National Reference Center for Campylobacters and Helicobacters where they were tested by molecular methods for detection of H. pylori and clarithromycin resistance by real-time PCR using a fluorescence resonance energy transfer-melting curve analysis (FRET-MCA) protocol, for detection of tetracycline resistance by real-time PCR on 16S rRNA genes (rrnA and rrnB), for detection of point mutations in the quinolone resistance-determining regions (QRDR) of H. pylori gyrA gene, associated with resistance to quinolones, by PCR and sequencing. RESULTS This study showed a high H. pylori prevalence (89%), low rates of clarithromycin and tetracycline resistance (1.7% and 2.5%, respectively), and a high rate of quinolone resistance (50%). CONCLUSION Therefore, the use of standard clarithromycin-based triple therapy is still possible as an empiric first-line treatment as well as prescription of bismuth-based quadruple therapy, which includes tetracycline, but not a levofloxacin-based triple therapy because of the high rate of resistance to fluoroquinolones.
Collapse
Affiliation(s)
| | | | - Rachelle Moyen
- Molecular and Cellular Biology Department, Technical and Sciences Faculty, Brazzaville, Congo
| | | | | | - O Obengui
- Microbiology and Haematology Department, Health Sciences Faculty, Brazzaville, Congo
| | | | - Etienne Nguimbi
- Molecular and Cellular Biology Department, Technical and Sciences Faculty, Brazzaville, Congo
| | - Rock Fabien Niama
- Molecular and Cellular Biology Department, Technical and Sciences Faculty, Brazzaville, Congo
| | - Jean Maurille Ouamba
- Chemistry plant and life unit, Technical and Sciences Faculty, Brazzaville, Congo
| | - Fidèle Yala
- Microbiology and Haematology Department, Health Sciences Faculty, Brazzaville, Congo
| | | | | | | | | | - Lucie Benejat
- French National Reference Center for Campylobacters and Helicobacters, University of Bordeaux, Bordeaux, France
| | - Elodie Sifre
- French National Reference Center for Campylobacters and Helicobacters, University of Bordeaux, Bordeaux, France
| | - Philippe Lehours
- INSERM U853, Bordeaux, France.,French National Reference Center for Campylobacters and Helicobacters, University of Bordeaux, Bordeaux, France
| | - Francis Megraud
- INSERM U853, Bordeaux, France.,French National Reference Center for Campylobacters and Helicobacters, University of Bordeaux, Bordeaux, France
| |
Collapse
|